Literature DB >> 1920313

Treatment of fulminant adult Still's disease with intravenous pulse methylprednisolone therapy.

M Khraishi1, A G Fam.   

Abstract

We describe a patient with fulminant adult onset Still's disease and multiple organ involvement. The acute flare persisted despite high doses of prednisone but responded to megadose intravenous pulse methylprednisolone therapy. This treatment modality may be useful in temporizing severe multisystem exacerbations of adult Still's disease.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1920313

Source DB:  PubMed          Journal:  J Rheumatol        ISSN： 0315-162X            Impact factor:   4.666


  6 in total

1.  Tumour necrosis factor alpha blocking agents in refractory adult Still's disease: an observational study of 20 cases.

Authors:  B Fautrel; J Sibilia; X Mariette; B Combe
Journal:  Ann Rheum Dis       Date:  2004-06-07       Impact factor: 19.103

Review 2.  Diagnosis and management of adult onset Still's disease.

Authors:  P Efthimiou; P K Paik; L Bielory
Journal:  Ann Rheum Dis       Date:  2005-10-11       Impact factor: 19.103

3.  Fever, rash, and arthritis in a woman with silicone gel breast implants.

Authors:  M C Genovese
Journal:  West J Med       Date:  1997-09

Review 4.  Adult-onset Still's disease: pathogenesis, clinical manifestations and therapeutic advances.

Authors:  Apostolos Kontzias; Petros Efthimiou
Journal:  Drugs       Date:  2008       Impact factor: 9.546

5.  Rare Manifestation of a Rare Disease, Acute Liver Failure in Adult Onset Still's Disease: Dramatic Response to Methylprednisolone Pulse Therapy-A Case Report and Review.

Authors:  Nalini Valluru; Venkata S Tammana; Michael Windham; Eyasu Mekonen; Rehana Begum; Andrew Sanderson
Journal:  Case Rep Med       Date:  2014-06-04

6.  Bibliometrics analysis on the research status and trends of adult-onset Still's disease: 1921-2021.

Authors:  Aining Qin; Jing Sun; Chao Gao; Chunying Li
Journal:  Front Immunol       Date:  2022-07-18       Impact factor: 8.786
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.